Peptides and the Blood-Brain Barrier: Why CNS Delivery Is Hard and What Intranasal Really Does

AI generatedsciencenootropic
This article was AI-generated for informational purposes only. It is not medical advice. Always verify claims with the cited sources.

A recurring claim in peptide marketing is that a given compound "crosses the blood-brain barrier" and acts directly on the brain. It is worth slowing down on that phrase, because the blood-brain barrier (BBB) is one of the most selective interfaces in human physiology, and most peptides are exactly the kind of molecule it is built to exclude. This is a research-log entry, not medical advice — the goal is to lay out what the barrier actually is, why peptides struggle with it, and what the evidence does and does not support about routes like intranasal delivery.

What the barrier actually is

The BBB is not a single membrane. It is a neurovascular unit built from brain microvascular endothelial cells, pericytes, astrocyte end-feet, and a basement membrane. The defining feature is that the endothelial cells lining brain capillaries are stitched together by tight junctions — overlapping protein complexes (claudins, occludin, and associated scaffolding) that form rows of occlusions between cells. These junctions all but eliminate the paracellular route, the gaps between cells that molecules slip through in most other tissues.

The consequence is that the brain is supplied almost entirely through the cells rather than between them, and that traffic is tightly policed by polarized transport systems. Small, lipid-soluble molecules can diffuse through membranes; nearly everything else needs a dedicated carrier or receptor. A frequently cited figure is that more than 98% of small-molecule drugs fail to reach the brain in meaningful concentrations. Large, polar molecules fare far worse.

Why peptides are hard cases

Peptides collide with the BBB on several fronts at once:

  • Size and polarity. Peptides are typically large and carry multiple hydrogen-bond donors and charged groups. Passive diffusion through the lipid endothelial membranes favors small, rigid, lipophilic molecules with few hydrogen bonds — roughly the opposite of a typical peptide.
  • No free ride on nutrient carriers. The BBB expresses transporters for glucose and individual amino acids, but the peptide bond itself blocks larger peptides from using amino-acid carrier systems. There is no general "peptide transporter" that ferries arbitrary sequences into the brain.
  • Enzymatic degradation. Peptides are substrates for peptidases in blood, on endothelial surfaces, and in tissue. Many are cleared or chopped up within minutes, so even a small membrane-crossing fraction is racing a short half-life.

    • This is why brain-penetration claims deserve scrutiny. A molecule producing a measurable effect after dosing is not proof it entered the brain intact and in pharmacologically relevant amounts — the effect could be peripheral, indirect, or driven by a tiny fraction that happened to cross.

    Strategies researchers actually use

    Because the default answer is "it doesn't cross well," the field has developed deliberate engineering strategies, each with trade-offs:

  • Lipidation and structural tuning. Increasing lipophilicity, reducing hydrogen-bond donors, shrinking molecular size, and adding rigidity can raise permeability — but these changes can also blunt the peptide's activity or stability.
  • Receptor-mediated transcytosis (RMT). Some peptides are engineered to hitchhike on receptors the BBB already uses — transferrin, insulin, IGF, and LDL-family receptors — via a three-step endocytosis-transport-exocytosis process. This is the basis of "molecular Trojan horse" shuttles.
  • Cell-penetrating peptides (CPPs) and carrier/nanoparticle systems, which attempt to drag cargo across via transcytosis or adsorptive uptake. These improve delivery in models but face their own proteolytic-stability and specificity problems.

    • These are active research approaches, not settled solutions — and importantly, they describe engineered constructs, not off-the-shelf peptides sold with brain claims.

    What intranasal really does

    The intranasal route is where marketing and evidence diverge most sharply. The appeal is a proposed "nose-to-brain" shortcut: peptides deposited high in the nasal cavity traveling along olfactory and trigeminal nerve pathways directly into the CNS, bypassing the BBB. In rodents this pathway looks efficient — intranasal nerve growth factor has produced markedly higher CNS concentrations than systemic dosing in some studies.

    The translation to humans is far shakier, for a concrete anatomical reason. In rodents the olfactory epithelium covers a large share of the nasal cavity; in humans it occupies under 10%, tucked into the uppermost recess where ordinary nasal sprays deposit poorly. Reviews note a genuine lack of robust evidence for meaningful nose-to-brain transport in humans. Studies on intranasal oxytocin illustrate the ambiguity: only very small amounts reach cerebrospinal fluid, while blood levels rise to supraphysiologic concentrations — so any central effect could be riding the bloodstream rather than a direct nasal-to-brain conduit.

    This is the backdrop for the popular Russian nootropic peptides. Both Selank and Semax are typically given as nasal sprays, and their central effects are largely inferred from functional and neuroimaging endpoints, not from direct human pharmacokinetics confirming intact brain entry. The clinical literature is dominated by Russian-language trials from a small set of institutions. That does not make the effects fake — it means the "bypasses the blood-brain barrier" framing outruns what has actually been measured in people.

    The takeaway

    The honest summary: the BBB is built to keep peptides out, crossing it is an engineering problem researchers are still solving, and intranasal delivery is a plausible-but-unproven shortcut in humans rather than a settled bypass. Treat confident brain-penetration claims as hypotheses to verify, not facts. Neither Selank nor Semax is FDA-approved (see FDA status), and this piece is a reference log entry, not a protocol.

    PepStash is a research log and reference tool. This article is educational and is not medical advice — it does not diagnose, treat, or recommend any protocol. Regulatory status and trial data change; always verify against primary sources and consult a licensed physician before making any decisions about your health.

    Not medical advice. For research purposes only. Consult a licensed physician before beginning any protocol.